Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM.

J Oncol Pract. 2013 Sep;9(5):223-9. doi: 10.1200/JOP.2013.000876.

2.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology..

Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285.

3.

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.

Clark MJ, Harris N, Griebsch I, Kaschinski D, Copley-Merriman C.

Health Qual Life Outcomes. 2014 Jul 4;12:104. doi: 10.1186/s12955-014-0104-5.

4.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI.

Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013.

PMID:
24631409
5.

Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.

van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R.

Eur Urol. 2014 Aug;66(2):330-6. doi: 10.1016/j.eururo.2013.08.007.

PMID:
23957945
6.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.

Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4.

PMID:
23142059
7.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A.

J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811.

PMID:
19364971
8.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874.

9.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844.

10.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045.

PMID:
25018038
11.

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ.

Cancer. 2013 Sep 1;119(17):3186-94. doi: 10.1002/cncr.28103.

12.

Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.

Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA.

Urol Oncol. 2011 Nov-Dec;29(6):670-5. doi: 10.1016/j.urolonc.2009.10.003.

13.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064.

PMID:
26306637
14.

Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.

Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, Misaki H, Noguchi K, Kubota Y, Uemura H.

PLoS One. 2012;7(10):e48186. doi: 10.1371/journal.pone.0048186.

15.
16.

Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, Antonarakis ES.

BJU Int. 2014 Dec;114(6b):E11-7. doi: 10.1111/bju.12531.

17.

Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.

Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M.

Urol Oncol. 2013 Aug;31(6):733-8. doi: 10.1016/j.urolonc.2011.06.006.

PMID:
21782481
18.
19.

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.

Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L.

Ann Oncol. 2012 Jul;23(7):1803-8. doi: 10.1093/annonc/mdr555.

PMID:
22112969
20.

Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old.

Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M.

Int Urol Nephrol. 2012 Dec;44(6):1697-703. doi: 10.1007/s11255-012-0223-z.

PMID:
22729777
Items per page

Supplemental Content

Support Center